$1.34
+0.04 (+2.68%)
Open$1.37
Previous Close$1.31
Day High$1.37
Day Low$1.27
52W High$8.81
52W Low$0.92
Volume—
Avg Volume49.3K
Market Cap25.90M
P/E Ratio—
EPS$-8.38
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+758.2% upside
Current
$1.34
$1.34
Target
$11.50
$11.50
$7.99
$11.50 avg
$12.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 25.07M | 987.4K | 951.3K |
| Net Income | -2,556,338,487 | -74,062 | -66,038 |
| Profit Margin | -374.3% | -7.5% | -6.9% |
| EBITDA | -2,086,380,232 | -123,235 | -109,691 |
| Free Cash Flow | — | -44,936 | -40,091 |
| Rev Growth | — | +23.6% | +13.9% |
| Debt/Equity | 0.01 | 1.06 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |